← Back to Search

Autophagy Inhibitor

Trametinib + Hydroxychloroquine for Pancreatic Cancer (THREAD Trial)

Phase 1
Recruiting
Led By Conan Kinsey, MD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Subject with histologically confirmed metastatic or locally advanced, unresectable pancreatic carcinoma
Must not have
Subjects who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
History of active major bleeding
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing hydroxychloroquine given with trametinib to see if it is effective and has manageable side effects for pancreatic cancer patients.

Who is the study for?
This trial is for adults with advanced pancreatic cancer that has spread and isn't eligible for surgery. Participants must have tried two standard treatments or refused them, have measurable disease, be able to provide a biopsy, and have functioning major organs. They should not be pregnant, agree to use effective contraception, and not have certain health conditions like active bleeding or recent major surgery.
What is being tested?
The study is testing the combination of Trametinib and Hydroxychloroquine in patients with pancreatic cancer. Trametinib blocks enzymes needed for cell growth while Hydroxychloroquine may prevent tumor cells from growing or spreading. The goal is to find the best dose of Hydroxychloroquine that can be given safely with Trametinib.
What are the potential side effects?
Potential side effects include issues related to liver function (like elevated enzyme levels), blood disorders (such as low neutrophil count), eye problems (including retinal vein occlusion), gastrointestinal disturbances, increased risk of infections due to immune system suppression, fatigue, skin reactions, and possible allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
My pancreatic cancer cannot be removed by surgery and has spread.
Select...
My liver enzymes are within the required range.
Select...
My cancer can be measured on a CT scan according to specific criteria.
Select...
My kidneys work well enough, with a creatinine clearance of at least 30 mL/min.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I had major surgery less than 3 weeks ago or am still dealing with its side effects.
Select...
I have had a major bleeding event in the past.
Select...
My brain metastases are stable for 4 weeks and I'm not on steroids.
Select...
I do not have a history of or current retinal vein occlusion, uncontrolled glaucoma, or conditions that increase blood thickness or clotting.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of dose-limiting toxicities during the DLT assessment window.
Secondary study objectives
Incidence of adverse events (AEs) for the duration of study treatment
Response Rate

Side effects data

From 2016 Phase 3 trial • 217 Patients • NCT02057250
13%
Upper respiratory tract infection
6%
Neutropenia
6%
Sinusitis
5%
Alanine aminotransferase increased
5%
Urinary tract infection
4%
Injection site erythema
4%
Accidental overdose
4%
Bronchitis
3%
Injection site pruritus
2%
Thrombocytopenia
2%
Nasopharyngitis
2%
Contusion
1%
Arthralgia
1%
Wolff-Parkinson-White syndrome
1%
Coronary artery occlusion
1%
Anaemia
1%
Leukopenia
1%
Lumbar spinal stenosis
1%
Transient ischaemic attack
1%
Vertebrobasilar insufficiency
1%
Chronic obstructive pulmonary disease
1%
Small intestinal obstruction
1%
Nephrolithiasis
1%
Cataract
1%
Thrombophlebitis superficial
1%
Vomiting
1%
Endometrial hyperplasia
1%
Traumatic arthritis
1%
Hypertension
1%
Pneumonia
1%
Pancreatic carcinoma metastatic
1%
Osteoarthritis
1%
Rheumatoid lung
1%
Pharyngitis
1%
Femoral neck fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sarilumab 150 mg by PFS (Extension Phase)
Sarilumab 150 mg by AID (AID Assessment Phase)
Sarilumab 150 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by AID (AID Assessment Phase)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (trametinib, hydroxychloroquine)Experimental Treatment2 Interventions
Patients receive trametinib PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trametinib
2014
Completed Phase 2
~1630
Hydroxychloroquine
2017
Completed Phase 4
~5350

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsIndustry Sponsor
2,914 Previous Clinical Trials
4,253,334 Total Patients Enrolled
University of UtahLead Sponsor
1,143 Previous Clinical Trials
1,697,093 Total Patients Enrolled
Conan Kinsey, MDPrincipal InvestigatorHuntsman Cancer Institute/ University of Utah

Media Library

Hydroxychloroquine (Autophagy Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03825289 — Phase 1
Pancreatic Endocrine Carcinoma Research Study Groups: Treatment (trametinib, hydroxychloroquine)
Pancreatic Endocrine Carcinoma Clinical Trial 2023: Hydroxychloroquine Highlights & Side Effects. Trial Name: NCT03825289 — Phase 1
Hydroxychloroquine (Autophagy Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03825289 — Phase 1
~1 spots leftby Jan 2025